NEW YORK – Guardant Health reported after the close of the market on Thursday that its third quarter 2020 revenues were up 23 percent year over year.
The liquid biopsy firm reported total revenues of $74.6 million for the quarter ended Sept. 30 compared to $60.8 million in the same period of 2019, beating the consensus Wall Street estimate of $65.9 million.
Guardant's oncology testing revenues in Q3 2020 rose 16 percent year over year to $60.4 million from $52.1 million. Development services revenues jumped up 65 percent to $14.2 million from $8.7 million in Q3 2019.